Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-DOTA-EB-RGD2 in Recurrent High-grade Glioma
NCT07655869Phase 1Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of 177Lu-DOTA-EB-RGD2 in glioma and glioblastoma (GBM) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Incidence of Dose-Limiting Toxicities at 6 weeks. Started Jun 2026; status: recruiting.
02
Drugs
177Lu-DOTA-EB-RGD2
03
Conditions
gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT07655869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07655869.